MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (INKT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
inkt · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$35.00
Consensus
$35.00
+208.6% upside
Low
$35.00
Median: $35 · Last Close: $11.34
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $11.91 | ↑ 5.00% |
1-day model range: $11.79–$12.02. Peak: $12.02 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · INKT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-15 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2025-07-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-07-14 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2025-03-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-15 | Baird | Maintains | Outperform→Outperform |
| 2024-11-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on MiNK Therapeutics, Inc. (INKT) stock. Of the recent 23 rating actions, 1 were upgrades and 2 were downgrades. 5 analysts currently cover INKT.
Analyst Recommendation Trends
INKT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 93.3% YoY
Revenue Next Year
$4M
↑ 3420.0% YoY
EPS This Year
$-2.75
EPS Next Year
$-2.85
↑ 4.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast INKT EPS of $-2.75 for the current fiscal year, based on estimates from 1 analysts. The INKT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The INKT stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus INKT price target is $35.00 (+208.6% upside), with an analyst consensus of Buy.
The INKT short-term stock prediction for tomorrow is $11.91 (+5.00%).
MiNK Therapeutics, Inc. trades on NASDAQ under the ticker INKT. The INKT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
INKT forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month INKT price target is $35.00, with a high forecast of $35.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +208.6% potential upside from the current price of $11.34.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.